This course has expired. View available courses.
Oncology
Advances in management of anaplastic lymphoma kinase (ALK)-positive lung cancer in the era of personalised medicine – Certificate of Completion
DURATION
PROFESSION
Specialist
# OF CREDITS
1.5
ACCREDITATION
Certificate of Completion
EXPIRY DATE
2017-10-28
Learning objectives
On completion of this program, participants will be better able to:
- Recall the epidemiology and clinical presentation of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
- Refer appropriate patients for ALK/ fluorescent in situ hybridisation (FISH) testing and coordinate multidisciplinary team management to optimise patient outcomes
- Review pharmaceutical benefit scheme (PBS) reimbursed treatment options for ALK-positive NSCLC and note the place of crizotinib as a new standard of care
- Evaluate clinical trial data on treatment of ALK-positive NSCLC including appreciation of the benefits of treating beyond disease progression